ExploreCME: Diving deep into PANCE Prep!

Cholesterol Mastery For Real-World Care

Subscriber Episode • • Phillip

Share episode

This episode is only available to subscribers.

ExploreCME: Diving deep into PANCE Prep! +

Get access to our entire back catalogue
SPEAKER_01:

Welcome back to the deep dive. Today we are getting into something that is less about abstract theory and uh much more about real-world life-saving clinical practice.

SPEAKER_00:

Yeah.

SPEAKER_01:

We're going to cut through all the dense literature on cholesterol and lipid disorders.

SPEAKER_00:

Aaron Powell, which can be a lot.

SPEAKER_01:

It can. Yeah. And you should think of this not as, you know, dry memorization, but as mastering what is arguably the single most important intervention point in preventive cardiology.

SPEAKER_00:

That is the perfect way to frame it. For anyone who needs to synthesize this kind of high-yield material, you know, if you're prepping for a big exam or just want to level up your patient care, this stuff is absolutely critical. Right. Our whole mission here is to move your understanding from just, you know, recognizing lab values to actually confidently applying the treatment algorithms.

SPEAKER_01:

Aaron Powell Because that's what it comes down to.

SPEAKER_00:

Trevor Burrus, it is. Because at the end of the day, managing lipids well is the same thing as managing a patient's risk of atherosclerotic cardiovascular disease. ASCVD.

SPEAKER_01:

Okay. So let's unpack all that. Let's start with the foundational science. I mean, to treat the problem, you have to understand the particles we're dealing with. Aaron Powell Of course. We know lipids, cholesterol, triglycerides are hydrophobic. They don't mix with blood. Trevor Burrus, Jr.

SPEAKER_00:

Right. They hate water. So they need transport vehicles. These are the lipoproteins, which are basically these little boats that are classified by their density. And if you understand their function, you understand why they cause disease.

SPEAKER_01:

Aaron Powell So give us that breakdown. Where do they come from and where are they going?

SPEAKER_00:

Okay. So we start with chylomicrons. These are just massive particles. They're formed in your gut, and their only job is to transport the dietary fat you just ate in your meal.

SPEAKER_01:

Just from your meal.

SPEAKER_00:

Yep. So they should be totally cleared from your circulation a few hours after you eat, which is why a proper fasting panel is so important.

SPEAKER_01:

Aaron Powell So if we actually see them in a fasting sample, something's really off with clearance.

SPEAKER_00:

Precisely. Next up is VLDL, very low density lipoprotein. Now, unlike hylomicons, VLDL is made in the liver. It's the liver's way of shipping out its own triglycerides to your peripheral tissues, you know, for energy or storage. And VLDL is the direct precursor to our main villain.

SPEAKER_01:

Aaron Powell Which is LDL. So the VLDL gives up its triglycerides, it gets smaller, denser, and all of a sudden you got the bad guy. Absolutely.

SPEAKER_00:

LDL, low density lipoprotein, is now just packed with cholesterol. It carries the vast majority of cholesterol in a standard fasting panel. And look, if you only remember one thing from this entire deep dive, let it be this. Elevated LDL is the primary undisputed causative driver of atherosclerosis, full stop.

SPEAKER_01:

And what about the particle that's supposed to be cleaning up this whole mess?

SPEAKER_00:

Uh that would be HDL, high density lipoprotein. It's involved in what we call reverse cholesterol transport. It's like a shuttle that picks up excess cholesterol from the periphery like from an artery wall and takes it back to the liver to be disposed of.

SPEAKER_01:

So higher HDL is good.

SPEAKER_00:

Aaron Powell It's generally good, yes. But what's interesting is that the current evidence shows that just trying to raise HDL therapeutically doesn't really reduce risk the way that lowering LDL does.

SPEAKER_01:

Okay, before we get to the plaques themselves, let's just quickly touch on that other rogue particle that's getting more attention now.

SPEAKER_00:

Aaron Powell You're talking about lycoprotein or LPA?

SPEAKER_01:

Right.

SPEAKER_00:

Yeah. Think of it as like a modified LDL particle that's super atherogenic and also pro-thrombotic, so it helps form clots.

SPEAKER_01:

Aaron Powell And it's genetic.

SPEAKER_00:

It is. It's genetically determined. So we often screen for it just once in a patient's lifetime, especially if they have premature or sort of unexplained heart disease.

SPEAKER_01:

Aaron Powell Okay, so the pathology nugget. If LDL is the main villain, how does it actually do the damage?

SPEAKER_00:

Aaron Powell It all starts when an LDL particle slips through the inner layer of the artery wall, the endothelium. Once it's trapped in there, it gets modified, mostly through oxidation. Okay. This oxidized LDL is highly inflammatory. It sends out a signal. And the macrophages, our immune system's cleanup crew, they rush in.

SPEAKER_01:

And they try to eat it?

SPEAKER_00:

They try to eat it, but they just gorge themselves on this oxidized LDL until they become these big, bloated, cholesterol-filled cells we call foam cells.

SPEAKER_01:

Foam cells, I remember that term.

SPEAKER_00:

And those foam cells are the absolute foundation of the fatty streak, which then grows into the unstable plaque that causes heart attacks and strokes. It's a whole chronic inflammatory process started by trapped LDL.

SPEAKER_01:

That's a perfect transition from the microscopic level right to the patient's bedside. So when we're sitting with a patient, what's the first thing we're digging for in their history?

SPEAKER_00:

You're digging for two main things: genetic risk and secondary causes. Family history is just paramount. You have to ask about premature ASCBD so heart disease in men younger than 55 or women younger than 65.

SPEAKER_01:

And if you find that.

SPEAKER_00:

If a patient's parent or sibling had a heart attack early in life, your suspicion for familial hypercholesterolemia has to go way up. And that needs aggressive intervention now.

SPEAKER_01:

But we can't just jump straight to the statins. The first rule here is to rule out other things that are causing the lipid problem.

SPEAKER_00:

Oh, absolutely. Before you commit a patient to lifelong therapy, you have to rule out secondary causes. You have to. This means screening for poorly controlled type 2 diabetes.

SPEAKER_01:

Which raises triglycerides.

SPEAKER_00:

Raises triglycerides, right. It means checking for hypothyroidism, which slows down LDL clearance, obesity, heavy alcohol use, nephrotic syndrome. All of these can throw lipids way off.

SPEAKER_01:

And what about the drugs they might already be on? I'm assuming a full med review is crucial.

SPEAKER_00:

It is, because some really common drugs can mess with the lipid panel. Think about chronic corticosterate use, some beta blockers, even thyzoide diuretics. If you can identify one of those, sometimes you can fix the problem just by adjusting a medication instead of adding another pill for cholesterol.

SPEAKER_01:

Okay, this is where it gets really interesting for the physical exam, because most dyslipidemia is silent, but when the numbers are just off the charts, the body gives us these visual clues. What are those uh pithognomonic findings?

SPEAKER_00:

They are rare, but when you see them, it's a game changer for your diagnosis. So if you see tendinous and Thomas, these hard yellowish nodules, especially on the Achilles tendon or over the knuckles, that is a dead giveaway for super high LDL levels and almost certainly genetic familial hyperclusterolemia.

SPEAKER_01:

So those nodules are the classic FH sign, suggesting a lifelong severe LDL problem. What about when it's the triglycerides that are sky high?

SPEAKER_00:

That looks totally different. You're looking for eruptive xantomus. These are clusters of red-yellow papules, often on the buttocks or the extensor surfaces of the arms and legs.

SPEAKER_01:

And that's a sign of what?

SPEAKER_00:

That's a visual scream for extreme hypertriglyceridemia. We're talking triglycerides well over a thousand. The immediate danger there is pancreatitis.

SPEAKER_01:

And wait, if the triglycerides get even higher, like over 2,000, there's something you can see in the eye, right?

SPEAKER_00:

Lipemia retinalis. It's dramatic. If you do a fundoscopic exam, the retinal arteries and veins look milky, almost cream colored. If you see that, you know that patient has a severe active risk for pancreatitis right now and they need urgent help.

SPEAKER_01:

That is fantastic context. Okay, let's move to the lab work, the diagnostic strategy. We get a standard lipid panel, but the centerpiece, the LDL, is usually calculated, and that comes with the big catch.

SPEAKER_00:

Aaron Powell It does. We usually rely on the Friedwald equation. Total cholesterol minus HDL minus triglycerides divided by five. But the crucial limitation is that this formula becomes completely unreliable if the patient's triglycerides are over 400.

SPEAKER_01:

400.

SPEAKER_00:

Yeah. At that point, the LDL number that the lab spits out is probably meaningless. You just can't trust it.

SPEAKER_01:

Aaron Powell So what's the clinical move then? If the TGs are high, how do we get a real sense of their risk?

SPEAKER_00:

Aaron Powell That's when we pivot to non-HDL cholesterol. It's a much simpler calculation. Just total cholesterol minus HDL. What's so powerful about non-HDL is that it captures all of the bad atherogenic particles, LDL, VLDL, remnants, LPA, all of it. It's often a better predictor of risk than LDL alone.

SPEAKER_01:

There's another bonus.

SPEAKER_00:

It's a huge bonus. It doesn't require the patient to be fasting. That makes screening so much easier.

SPEAKER_01:

Okay, so beyond the standard panel, let's say we have a patient who's in that intermediate risk zone. We're on the fence about starting a lifelong medication. What's a good tiebreaker test?

SPEAKER_00:

The coronary artery calcium score. The CAC score. It's a non-contrast CT scan that literally measures the amount of established plaque in the coronary arteries. It's an incredibly powerful tool.

SPEAKER_01:

How does it change your management?

SPEAKER_00:

Well, for that intermediate risk patient, if their score is zero, no calcified plaque at all, it's often very safe to defer statin therapy, even if the risk calculator says maybe. But if the score is high, it pushes them firmly into the treatment camp.

unknown:

Got it.

SPEAKER_00:

And we also use lipoprotein, like we mentioned, for that one-time genetic risk check-in.

SPEAKER_01:

So this brings us to risk stratification, which is really the heart of modern management. We're not just treating a number, we're treating the patient's overall ASCVD risk. So how do we define those four main risk groups?

SPEAKER_00:

The guidelines make this very clear. It all depends on where the patient falls. Number one, clinical ASCVD.

SPEAKER_01:

Secondary prevention.

SPEAKER_00:

Exactly. They've already had a heart attack, a stroke, PAD, something. They automatically get aggressive therapy. No question.

SPEAKER_01:

Okay, group two.

SPEAKER_00:

Severe hypercholesteremia. This is usually defined as an LDL of 190 or higher. This group likely has familial hypercholesteremia, and they also need immediate high-intensity treatment.

SPEAKER_01:

Group three.

SPEAKER_00:

Diabetes mellitus. Any adult from age 40 to 75 with diabetes automatically gets classified as at least moderate risk, even if their lipids look totally normal.

SPEAKER_01:

And then there's everyone else.

SPEAKER_00:

Exactly. Primary prevention. For all other adults in that age range, we use the pooled cohort equations to calculate their 10-year risk. And if that risk score is 7.5% or higher, that generally triggers a discussion about starting a statin.

SPEAKER_01:

But sometimes that risk score is a little fuzzy, right? Put someone in that borderline category, say 6% risk, how do we make the call then?

SPEAKER_00:

That's where risk enhancing factors are so important. We look for things like chronic inflammatory conditions, rheumatoid arthritis, even HIV or metabolic syndrome, chronic kidney disease, a really strong family history.

SPEAKER_01:

And these act as tiebreakers.

SPEAKER_00:

Exactly. If a patient is intermediate risk, but they have one or more of these enhancers, you're much more likely to push them towards starting that statin.

SPEAKER_01:

Okay, so what does this all mean for management? Clinical intervention. The whole thing seems to be built on a foundation of statins.

SPEAKER_00:

It is. Statins, the HMG CoA reductase inhibitors, are the undisputed cornerstone. Their mechanism is just brilliant. They block the main enzyme from making cholesterol, which then makes the liver put out way more LDL receptors to grab cholesterol from the blood.

SPEAKER_01:

And they do more than just lower the numbers.

SPEAKER_00:

So much more. They stabilize plaque, they reduce inflammation, and most importantly, they reduce overall mortality and cardiovascular events.

SPEAKER_01:

Aaron Powell And it's not just about starting any statin right. Yeah. The clinical skill is in choosing the right intensity to get that LDL down.

SPEAKER_00:

Aaron Powell Precisely. We talk about intensity. High intensity statins, that's your atorvastatin 40 to 80 milligrams, or roseugostatin 20 to 40, they're expected to lower LDL by at least 50%. Wow. We use those for our highest risk patients. And while they're incredibly safe, we do have to counsel patients about myalgias, you know, common muscle aches.

SPEAKER_01:

So if a patient calls and says their muscles are aching, what's the immediate next step?

SPEAKER_00:

First, we have to distinguish simple myalgia from true myositis or the very rare but severe rebdomyolysis. We check a CK level. If it's normal, we might just try a lower dose or switch to a different statin.

SPEAKER_01:

And if the CK is high?

SPEAKER_00:

If it's significantly elevated, we stop the drug immediately. And we also have to tell patients that there's a small but real risk of new onset diabetes with statins. But the cardiovascular benefits just overwhelmingly outweigh that risk.

SPEAKER_01:

Let's go back to that secondary prevention patient. We've started a high-intensity satin. There's still high risk, but their LDL isn't that goal. What's the first thing you add?

SPEAKER_00:

The first line add on therapy is azetomy. It works completely differently. It blocks cholesterol absorption in the gut. Adding it on can knock the LDL down another 15 to 20%.

SPEAKER_01:

But what if that's still not enough? Say a patient who's had two heart attacks and they're on a statin, an ezzomy, still not a goal. Then you bring out the big guns.

SPEAKER_00:

Then you bring out the PCS-K9 inhibitors. These drugs are just fascinating. They block a protein, PCS-K9, that degrades LDL receptors. So by blocking the blocker, you leave way more receptors on the liver surface to just pull cholesterol out of the blood 24-7.

SPEAKER_01:

And the LDL drop is huge.

SPEAKER_00:

It's massive. We're talking 60% reductions. They're reserved for the absolute highest risk patients or those with severe FH.

SPEAKER_01:

Okay, let's pivot for a second from cholesterol to triglycerides. We talked about that pancreatitis risk when they're over 500.

SPEAKER_00:

Yeah.

SPEAKER_01:

How do you manage that threat?

SPEAKER_00:

The number one goal has to be preventing pancreatitis. That means an immediate, extremely low-fat diet. And for medications, we usually turn to fibrates like phenofibrate. They're excellent at lowering triglycerides.

SPEAKER_01:

So there's a big safety warning here.

SPEAKER_00:

A huge one. Gemphi Brazil, which is an older fibrate, should generally be avoided if the patient is also on a statin. The risk of rhabdomyolysis is just too high. Phenofibrate is the much safer choice if you need that combination.

SPEAKER_01:

And there was that specific omega-3 that showed a big benefit, but only for a certain group.

unknown:

Right.

SPEAKER_00:

Icosapinethyl. It's a highly purified form of EPA. The reduced IT trial showed that for patients who already had CVD or diabetes, and their triglycerides were still over 150 on a statin.

SPEAKER_01:

Okay.

SPEAKER_00:

Adding icosapin ethyl on top of all that significantly reduced major cardiovascular events, it's a very precise tool for a very specific population.

SPEAKER_01:

So let's just recap that core management algorithm for our secondary prevention patient, the person with known ASCVD.

SPEAKER_00:

You start with a high-intensity statin. The goal is an LDL less than 70. For a very high-risk patient, maybe someone with multiple events, the goal is even lower, like less than 55.

SPEAKER_01:

And if you don't hit that, you step up.

SPEAKER_00:

Statin plus his etama, if you're still not at goal, it's statin plus his etamae plus a PCSK9 inhibitor. That's the ladder you climb to crush their residual risk.

SPEAKER_01:

Okay, finally, let's talk health maintenance and prevention. What are the lifestyle pillars that support all this medication?

SPEAKER_00:

Dietary therapy is absolutely foundational, and we should be specific. We strongly recommend the Mediterranean diet model. It's about replacing saturated fats like from butter and red meat with healthy monounsaturated fats.

SPEAKER_01:

Like olive oil and avocado.

SPEAKER_00:

Olive oil, avocado is nuts. That is so much more effective than just trying to avoid all fat.

SPEAKER_01:

Are there any specific foods that can give you an extra little push in lowering LDL?

SPEAKER_00:

Absolutely. Soluble fiber so from things like oatmeal, beans, barley, and also plant sterols can give you a measurable LDL reduction of about 5 to 10%. And you have to teach patients to cut saturated fat to less than 7% of their calories and to completely avoid trans fats.

SPEAKER_01:

One quick thing that always comes up is suppalants, red yeast rice.

SPEAKER_00:

Yeah, red yeast rice naturally contains a statin, levastatin, but because it's an unregulated supplement, the dose is all over the place, the quality is variable. We should always recommend a prescription statin where we know the dose and the purity.

SPEAKER_01:

And before we wrap, a quick clinical tip on a special population that has a very high ASCVD risk.

SPEAKER_00:

Yes, patients with HIV who are on antiretroviral therapy, they have a much higher ASCVD risk, mostly from chronic inflammation. And there was a landmark study, the reprieve trial, which showed very clearly that statins cut major cardiovascular events by 35% in this specific population. This is strong support for using statins proactively in most patients with HIV.

SPEAKER_01:

This has been a complete journey. We started with the basic science, identifying LDL as the villain, and then we learned to spot those visual clues like tendinus antomas. We tackled the diagnostic issues like the Friedwald limitation and using the SAC score as that perfect tiebreaker. And then we walked right through the four risk groups and the step-up treatment plans.

SPEAKER_00:

And the central clinical concept here, the main takeaway, is you have to treat the patient's overall risk, not just one number. Use those guidelines to decide who to treat. Always rule out secondary causes first, and use those extra tools like the CAC score to help you decide in those gray areas.

SPEAKER_01:

Which brings us to our final thought for you to chew on. We talked about how unbelievably effective these PCS canine inhibitors are. They let us push LDL levels down to levels we've never seen before. I mean, into the teens or twenties.

SPEAKER_00:

Super low.

SPEAKER_01:

So if we can safely maintain these ultra low LDL levels, what does that tell us about the absolute ceiling on how low LDL needs to be for maximum protection? Is there a point where lower is always better? Or do we eventually hit a floor where the benefit just plateaus? Something to think about as you define what optimal really means.

SPEAKER_00:

That's a fundamental question, and it's really driving a lot of the current research.

SPEAKER_01:

Thank you for joining us for the deep dive. We'll see you next time.